A patient-oriented risk-benefit analysis of pathogen-inactivated blood components: Application to apheresis platelets in the United States

Transfusion

Volumn 53, Issue 7, 2013, Pages 1603-1618

  Kleinman, Steven ^a   Reed, William ^a   Stassinopoulos, Adonis ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

NONOXINOL 9;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ALLOIMMUNIZATION; APHERESIS; ARTICLE; BACTERIUM CONTAMINATION; BLOOD COMPONENT; BLOOD TRANSFUSION REACTION; CLINICAL STUDY; CYTOMEGALOVIRUS INFECTION; HUMAN; OBSERVATIONAL STUDY; PNEUMONIA; RETROSPECTIVE STUDY; THROMBOCYTE; THROMBOCYTE TRANSFUSION; TRANSFUSION ASSOCIATED GRAFT VERSUS HOST DISEASE; UNITED STATES;

ANTISEPSIS; BLOOD PLATELETS; COMMUNICABLE DISEASES, EMERGING; CYTOMEGALOVIRUS INFECTIONS; HUMANS; PLATELET TRANSFUSION; PLATELETPHERESIS; RISK ASSESSMENT; UNITED STATES;

EID: 84878112370     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2012.03928.x     Document Type: Article

References (96)

1. Stramer SL,. Current risks of transfusion-transmitted agents: a review. Arch Pathol Lab Med 2007; 131: 702-707.
2. Zou S, Stramer SL, Notari EP, Kuhns MC, Krysztof D, Musavi F, Fang CT, Dodd RY,. Current incidence and residual risk of hepatitis B infection among blood donors in the United States. Transfusion 2009; 49: 1609-1620.
3. Dodd RY, Notari EP 4th, Stramer SL,. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002; 42: 975-979.
4. Lin L, Cook DN, Wiesehahn GP, Alfonso R, Behrman B, Cimino GD, Corten L, Damonte PB, Dikeman R, Dupuis K, Fang YM, Hanson CV, Hearst JE, Lin CY, Londe HF, Metchette K, Nerio AT, Pu JT, Reames AA, Rheinschmidt M, Tessman J, Isaacs ST, Wollowitz S, Corash L,. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 1997; 37: 423-435.
5. Irsch J, Lin L,. Pathogen inactivation of platelet and plasma blood components for transfusion using the INTERCEPT Blood System. Transfus Med Hemother 2011; 38: 19-31.
6. Wollowitz S,. Fundamentals of the psoralen-based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma. Semin Hematol 2001; 38: 4-11.
7. Ciaravino V, McCullough T, Cimino G,. The role of toxicology assessment in transfusion medicine. Transfusion 2003; 43: 1481-1492.
8. Ciaravino V, McCullough T, Cimino G, Sullivan T,. Preclinical safety profile of plasma prepared using the INTERCEPT Blood System. Vox Sang 2003; 85: 171-182.
9. Van Voorhis WC, Barrett LK, Eastman RT, Alfonso R, Dupuis K,. Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCl) and long-wavelength UV. Antimicrob Agents Chemother 2003; 47: 475-479.
10. Eastman RT, Barrett LK, Dupuis K, Buckner FS, Van Voorhis WC,. Leishmania inactivation in human pheresis platelets by a psoralen (amotosalen HCl) and long-wavelength ultraviolet irradiation. Transfusion 2005; 45: 1459-1463.
11. Greeno E, McCullough J, Weisdorf D,. Platelet utilization and the transfusion trigger: a prospective analysis. Transfusion 2007; 47: 201-205.
12. Meehan KR, Matias CO, Rathore SS, Sandler SG, Kallich J, LaBrecque J, Erder H, Schulman KA,. Platelet transfusions: utilization and associated costs in a tertiary care hospital. Am J Hematol 2000; 64: 251-256.
13. McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, Stadtmauer EA, Lopez-Plaza I, Coutre S, Strauss RG, Goodnough LT, Fridey JL, Raife T, Cable R, Murphy S, Howard F 4th, Davis K, Lin JS, Metzel P, Corash L, Koutsoukos A, Lin L, Buchholz DH, Conlan MG,. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT trial. Blood 2004; 104: 1534-1541.
14. Slichter SJ, Kaufman RM, Assmann SF, McCullough J, Triulzi DJ, Strauss RG, Gernsheimer TB, Ness PM, Brecher ME, Josephson CD, Konkle BA, Woodson RD, Ortel TL, Hillyer CD, Skerrett DL, McCrae KR, Sloan SR, Uhl L, George JN, Aquino VM, Manno CS, McFarland JG, Hess JR, Leissinger C, Granger S,. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010; 362: 600-613.
15. Solh M, Brunstein C, Morgan S, Weisdorf D,. Platelet and red blood cell utilization and transfusion independence in umbilical cord blood and allogeneic peripheral blood hematopoietic cell transplants. Biol Blood Marrow Transplant 2011; 17: 710-716.
16. Whitaker BI, Henry RA,. Report of the US Department of Health and Human Services. The 2009 national blood collection and utilization survey report. Washington DC: US Department of Health and Human Services, Office of the Assistant Secretary for Health, 2011.
17. Murphy WG, Foley M, Doherty C, Tierney G, Kinsella A, Salami A, Cadden E, Coakley P,. Screening platelet concentrates for bacterial contamination: low numbers of bacteria and slow growth in contaminated units mandate an alternative approach to product safety. Vox Sang 2008; 95: 13-19.
18. Corash L,. Bacterial contamination of platelet components: potential solutions to prevent transfusion-related sepsis. Expert Rev Hematol 2011; 4: 509-525.
19. Jacobs MR, Good CE, Lazarus HM, Yomtovian RA,. Relationship between bacterial load, species virulence, and transfusion reaction with transfusion of bacterially contaminated platelets. Clin Infect Dis 2008; 46: 1214-1220.
20. Dumont LJ, Kleinman S, Murphy JR, Lippincott R, Schuyler R, Houghton J, Metzel P,. Screening of single-donor apheresis platelets for bacterial contamination: the PASSPORT study results. Transfusion 2010; 50: 589-599.
21. Jacobs MR, Smith D, Heaton WA, Zantek ND, Good CE,; PGD Study Group. Detection of bacterial contamination in prestorage culture-negative apheresis platelets on day of issue with the Pan Genera Detection test. Transfusion 2011; 51: 2573-2582.
22. Pearce S, Rowe GP, Field SP,. Screening of platelets for bacterial contamination at the Welsh Blood Service. Transfus Med 2011; 21: 25-32.
23. Walther-Wenke G, Daubener W, Heiden M, Hoch J, Hornei B, Volkers P, von, Konig CH,; Working Party on Bacteria Safety in Transfusion Medicine of the National Advisory Committee Blood of the German Federal Ministry of Health, Berlin, Germany. Effect of safety measures on bacterial contamination rates of blood components in Germany. Transfus Med Hemother 2011; 38: 231-235.
24. Walther-Wenke G, Schmidt M,. Impact of bacterial contamination on blood supply. Transfus Med Hemother 2011; 38: 229-230.
25. Walther-Wenke G, Wirsing von Konig CH, Daubener W, Heiden M, Hoch J, Hornei B, Volkers P,; Working Party on Bacteria Safety in Transfusion Medicine, Advisory Board of the German Ministry of Health, Berlin. Monitoring bacterial contamination of blood components in Germany: effect of contamination reduction measures. Vox Sang 2011; 100: 359-366.
26. National Haemovigilance Programme. Annual report. 2010. New Zealand Blood Service, Wellington, New Zealand, p 34-35).
27. Jenkins C, Ramirez-Arcos S, Goldman M, Devine DV,. Bacterial contamination in platelets: incremental improvements drive down but do not eliminate risk. Transfusion 2011; 51: 2555-2565.
28. Eder AF, Kennedy JM, Dy BA, Notari EP, Skeate R, Bachowski G, Mair DC, Webb JS, Wagner SJ, Dodd RY, Benjamin RJ,; American Red Cross Regional Blood Centers. Limiting and detecting bacterial contamination of apheresis platelets: inlet-line diversion and increased culture volume improve component safety. Transfusion 2009; 49: 1554-1563.
29. Behrendt CE, Rosenthal J, Bolotin E, Nakamura R, Zaia J, Forman SJ,. Donor and recipient CMV serostatus and outcome of pediatric allogeneic HSCT for acute leukemia in the era of CMV-preemptive therapy. Biol Blood Marrow Transplant 2009; 15: 54-60.
30. Narvios AB, de Lima M, Shah H, Lichtiger B,. Transfusion of leukoreduced cellular blood components from cytomegalovirus-unscreened donors in allogeneic hematopoietic transplant recipients: analysis of 72 recipients. Bone Marrow Transplant 2005; 36: 499-501.
31. Vamvakas EC,. Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis. Transfus Med Rev 2005; 19: 181-199.
32. Wu Y, Zou S, Cable R, Dorsey K, Tang Y, Hapip CA, Melmed R, Trouern-Trend J, Wang JH, Champion M, Fang C, Dodd R,. Direct assessment of cytomegalovirus transfusion-transmitted risks after universal leukoreduction. Transfusion 2010; 50: 776-786.
33. Thiele T, Kruger W, Zimmermann K, Ittermann T, Wessel A, Steinmetz I, Dolken G, Greinacher A,. Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME). Transfusion 2011; 51: 2620-2626.
34. Ziemann M, Krueger S, Maier AB, Unmack A, Goerg S, Hennig H,. High prevalence of cytomegalovirus DNA in plasma samples of blood donors in connection with seroconversion. Transfusion 2007; 47: 1972-1983.
35. Staras SA, Dollard SC, Radford KW, Flanders WD, Pass RF, Cannon MJ,. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis 2006; 43: 1143-1151.
36. Bate SL, Dollard SC, Cannon MJ,. Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004. Clin Infect Dis 2010; 50: 1439-1447.
37. Kleinman S, Cameron C, Custer B, Busch M, Katz L, Kralj B, Matheson I, Murphy K, Preiksaitis J, Devine D,. Modeling the risk of an emerging pathogen entering the Canadian blood supply. Transfusion 2010; 50: 2592-2606.
38. Perkins HA, Busch MP,. Transfusion-associated infections: 50 years of relentless challenges and remarkable progress. Transfusion 2010; 50: 2080-2099.
39. Stramer SL, Linnen JM, Carrick JM, Foster GA, Krysztof DE, Zou S, Dodd RY, Tirado-Marrero LM, Hunsperger E, Santiago GA, Munoz-Jordan JL, Tomashek KM,. Dengue viremia in blood donors identified by RNA and detection of dengue transfusion transmission during the 2007 dengue outbreak in Puerto Rico. Transfusion 2012; 52: 1657-1666.
40. Lin L, Dikeman R, Molini B, Lukehart SA, Lane R, Dupuis K, Metzel P, Corash L,. Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion 2004; 44: 1496-1504.
41. Schmidt MS, Kapzrak B, Pfeiffer H-U, Henschler R, Sireis W, Seifried E,. Efficiency of the pathogen inactivation system INTERCEPT under experimental conditions. Vox Sang 2011; 101 (Suppl 1): 226-227.
42. Cazenave JP, Corash L, Waller C, Kientz D, Isola H, Mendel I, Laforet M, Sherman C,. The frequency of transfusion related sepsis and death imputed to platelet components: impact of pathogen inactivation. 14th International Haemovigilance Seminar-Presentation 2012.
43. Andreu G, Morel P, Forestier F, Debeir J, Rebibo D, Janvier G, Herve P,. Hemovigilance network in France: organization and analysis of immediate transfusion incident reports from 1994 to 1998. Transfusion 2002; 42: 1356-1364.
44. Rebibo D, Hauser L, Slimani A, Herve P, Andreu G,. The French Haemovigilance System: organization and results for 2003. Transfus Apher Sci 2004; 31: 145-153.
45. Carlier M, Vo Mai MP, Fauveau L, Ounnoughene N, Sandid I, Renaudier P,. [Seventeen years of haemovigilance in France: assessment and outlook]. Transfus Clin Biol 2011; 18: 140-150.
46. Roback JD, Conlan M, Drew WL, Ljungman P, Nichols WG, Preiksaitis JK,. The role of photochemical treatment with amotosalen and UV-A light in the prevention of transfusion-transmitted cytomegalovirus infections. Transfus Med Rev 2006; 20: 45-56.
47. Lin L, Hanson CV, Alter HJ, Jauvin V, Bernard KA, Murthy KK, Metzel P, Corash L,. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 2005; 45: 580-590.
48. Pinna D, Sampson-Johannes A, Clementi M, Poli G, Rossini S, Lin L, Vicenzi E,. Amotosalen photochemical inactivation of severe acute respiratory syndrome coronavirus in human platelet concentrates. Transfus Med 2005; 15: 269-276.
49. Sawyer L, Hanson D, Castro G, Luckett W, Dubensky TW Jr, Stassinopoulos A,. Inactivation of parvovirus B19 in human platelet concentrates by treatment with amotosalen and ultraviolet A illumination. Transfusion 2007; 47: 1062-1070.
50. Grellier P, Benach J, Labaied M, Charneau S, Gil H, Monsalve G, Alfonso R, Sawyer L, Lin L, Steiert M, Dupuis K,. Photochemical inactivation with amotosalen and long-wavelength ultraviolet light of Plasmodium and Babesia in platelet and plasma components. Transfusion 2008; 48: 1676-1684.
51. Sawyer L, Higgs S, Tsetsarkin K, Vanlandingham D, Johnson R, Kodner C, Kinsey J, Hanson D, Sampson-Johannes A,. Inactivation of transfusion-transmitted vector borne pathogens. Vox Sang 2009; 96 (S1): 233-234.
52. Dupuis K, Sawyer L,. Inactivation of influenza virus type A H5N1 in platelets and plasma by treatment with the INTERCEPT blood system. Vox Sang 2008; 95 (S1): 301.
53. Corash L, Lin L,. Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease. Bone Marrow Transplant 2004; 33: 1-7.
54. Lin L, Corash L, Osselaer JC,. Protection against TA-GVHD due to platelet transfusion by using pathogen inactivation with the INTERCEPT blood system™-gamma irradiation is not the only answer. Haematologica Edicion Espanol 2010; 95: 86-93.
55. Mintz PD,. Cesium cessation? An advantage of pathogen reduction treatments. Transfusion 2011; 51: 1369-1376.
56. Ruhl H, Bein G, Sachs UJ,. Transfusion-associated graft-versus-host disease. Transfus Med Rev 2009; 23: 62-71.
57. Dwyre DM, Holland PV,. Transfusion-associated graft-versus-host disease. Vox Sang 2008; 95: 85-93.
58. Cazenave JP, Isola H, Waller C, Mendel I, Kientz D, Laforet M, Raidot JP, Kandel G, Wiesel ML, Corash L,. Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period. Transfusion 2011; 51: 622-629.
59. Lin L, Stassinopoulos A, Corash L,. Cumulative clinical data of INTERCEPT blood system for platelets demonstrate ability to replace gamma irradiation in routine clinical use for TA-GVHD prevention. Vox Sang 2011; 101 (S1): 184-185.
60. TRAP Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997; 337: 1861-1869.
61. Slichter SJ,. Platelet transfusion therapy. Hematol Oncol Clin North Am 2007; 21: 697-729.
62. Hei DJ, Grass J, Lin L, Corash L, Cimino G,. Elimination of cytokine production in stored platelet concentrate aliquots by photochemical treatment with psoralen plus ultraviolet A light. Transfusion 1999; 39: 239-248.
63. Grass JA, Wafa T, Reames A, Wages D, Corash L, Ferrara JL, Lin L,. Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Blood 1999; 93: 3140-3147.
64. Grass JA, Hei DJ, Metchette K, Cimino GD, Wiesehahn GP, Corash L, Lin L,. Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood 1998; 91: 2180-2188.
65. Fiebig E, Hirschkorn DF, Maino VC, Grass JA, Lin L, Busch MP,. Assessment of donor T-cell function in cellular blood components by the CD69 induction assay: effects of storage, gamma radiation, and photochemical treatment. Transfusion 2000; 40: 761-770.
66. Osselaer JC, Vandendaele M-C, Guldenpfennig M, Sherman C, Corash L, Doyen C,. Influence on HLA alloimmunisation frequency in hematology patients supported with INTERCEPT pathogen inactivated (PI) platelet components (PC). Transfusion 2011; 51 (S3): 122A.
67. Morrell CN,. Immunomodulatory mediators in platelet transfusion reactions. Hematology Am Soc Hematol Educ Program 2011; 2011: 470-474.
68. Patterson BJ, Freedman J, Blanchette V, Sher G, Pinkerton P, Hannach B, Meharchand J, Lau W, Boyce N, Pinchefsky E, Tasev T, Pinchefsky J, Poon S, Shulman L, Mac KP, Thomas K, Blanchette N, Greenspan D, Panzarella T,. Effect of premedication guidelines and leukoreduction on the rate of febrile nonhaemolytic platelet transfusion reactions. Transfus Med 2000; 10: 199-206.
69. Cazenave JP, Kientz D, Mendel I, Isola H, Waller C,. Hemovigilance surveillance of platelet components prepared with pathogen inactivation treatment during a three year period. 12th International Hemovigilance Seminar-Presentation 2010.
70. Vamvakas EC,. Meta-analysis of the studies of bleeding complications of platelets pathogen-reduced with the Intercept system. Vox Sang 2011; 102: 302-316.
71. Vamvakas EC,. Meta-analysis of the randomized controlled trials of the hemostatic efficacy and capacity of pathogen-reduced platelets. Transfusion 2011; 51: 1058-1071.
72. Snyder E, McCullough J, Slichter SJ, Strauss RG, Lopez-Plaza I, Lin JS, Corash L, Conlan MG, Group SS,. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion 2005; 45: 1864-1875.
73. Corash L,. The hemostatic efficacy of platelet components prepared with pathogen inactivation. Transfusion 2011; 51: 1355-1356; author reply 1356-7.
74. Cid J, Escolar G, Lozano M,. Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta-analysis of randomized controlled trials. Vox Sang 2012 May 7. doi: 10.1111/j.1423-0410.2012.01614.x. [Epub ahead of print]
75. Kerkhoffs JL, van Putten WL, Novotny VM, Te Boekhorst PA, Schipperus MR, Zwaginga JJ, van, Pampus LC, de, Greef GE, Luten M, Huijgens PC, Brand A, van, Rhenen DJ,; Dutch-Belgian HOVON Cooperative Group. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 2010; 150: 209-217.
76. van Rhenen D, Gulliksson H, Cazenave JP, Pamphilon D, Ljungman P, Kluter H, Vermeij H, Kappers-Klunne M, de, Greef G, Laforet M, Lioure B, Davis K, Marblie S, Mayaudon V, Flament J, Conlan M, Lin L, Metzel P, Buchholz D, Corash L,; euroSPRITE trial. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003; 101: 2426-2433.
77. Lozano M, Knutson F, Tardivel R, Cid J, Maymo RM, Lof H, Roddie H, Pelly J, Docherty A, Sherman C, Lin L, Propst M, Corash L, Prowse C,. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. Br J Haematol 2011; 153: 393-401.
78. Osselaer JC, Cazenave JP, Lambermont M, Garraud O, Hidajat M, Barbolla L, Tardivel R, Defoin L, Waller C, Mendel I, Raidot JP, Kandel G, De Meuter R, Fabrigli P, Dehenau D, Arroyo JL, Padron F, Gouezec H, Corral M, Jacquet M, Sundin D, Lin L, Corash L,. An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang 2008; 94: 315-323.
79. Cazenave JP, Waller C, Kientz D,. Inventory management. Vox Sang 2010; 98: e313-325.
80. Osselaer JC, De Coene B, Thonet MC, Corlier C, Jamart J, Doyen C,. The incidence of CNS bleeding in transfusion dependent patients before and after introduction of pathogen inactivated platelet components: a six-year hemovigilance survey. 12th International Haemovigilance Seminar-Presentation 2010.
81. Corash L, Lin JS, Sherman CD, Eiden J,. Determination of acute lung injury after repeated platelet transfusions. Blood 2011; 117: 1014-1020.
82. Osselaer JC, Messe N, Hervig T, Bueno J, Castro E, Espinosa A, Accorsi P, Junge K, Jacquet M, Flament J, Corash L,. A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. Transfusion 2008; 48: 1061-1071.
83. Janetzko K, Cazenave JP, Kluter H, Kientz D, Michel M, Beris P, Lioure B, Hastka J, Marblie S, Mayaudon V, Lin L, Lin JS, Conlan MG, Flament J,. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion 2005; 45: 1443-1452.
84. Osselaer JC, Doyen C, Defoin L, Debry C, Goffaux M, Messe N, Van Hooydonk M, Bosly A, Lin JS, Lin L, Corash L,. Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use. Transfusion 2009; 49: 1412-1422.
85. Agence française de sécurité sanitaire des produits de santé (AFSSAPS). AFSSAPS annual haemovigilance reports for 2009-2011. [cited 2012 Aug 20]. Available from: URL: http://www.afssaps.fr/Activites/ Hemovigilance/Hemovigilance/(offset)/0
86. Klein HG, Anderson D, Bernardi MJ, Cable R, Carey W, Hoch JS, Robitaille N, Sivilotti ML, Smaill F,. Pathogen inactivation: making decisions about new technologies-preliminary report of a consensus conference. Vox Sang 2007; 93: 179-182.
87. Alter HJ,. Pathogen reduction: a precautionary principle paradigm. Transfus Med Rev 2008; 22: 97-102.
88. Cazenave JP,. [Pathogen inactivation in platelet concentrates: the French experience]. Transfus Clin Biol 2011; 18: 478-484.
89. Infanti L, Stebler C, Job S, Ruesch M, Gratwohl A, Irsch J, Lin L, Buser A,. Pathogen-inactivation of platelet components with the INTERCEPT Blood System: a cohort study. Transfus Apher Sci 2011; 45: 175-181.
90. Tice RR, Gatehouse D, Kirkland D, Speit G,. The pathogen reduction treatment of platelets with S-59 HCl (Amotosalen) plus ultraviolet A light: genotoxicity profile and hazard assessment. Mutat Res 2007; 630: 50-68.
91. Castrillo Fernandez A, Arcas Otero C, Rodriguez Calvo MI,. Pathogen reduction treatment using amotosalen and ultraviolet-A light: process control. Vox Sang 2011; 101 (Suppl 1): 178-179.
92. Girona-Llobera E, Galmes-Trueba A, Jimenez-Marco T, Sedeno M, Muncunill J,. Platelet pathogen inactivation improves platelet components management and lowers the production cost associated with expiration. Transfusion 2010; 50 (Suppl): 52A.
93. Domanovic D, Cukjati M, Milojkovic A,. Two years of experience with the transfusion of pathogen inactivated platelets using the INTERCEPT blood system and 7 day storage. Vox Sang 2011; 101 (Suppl 1): 186.
94. Goslings D, Lodemann P, Yavuzcan G, Glauser A, Valek A, Frey BM,. Validation and implementation of the INTERCEPT blood system for platelets for pathogen inactivation of apheresis and buffy-coat products at one of the biggest regional blood-centers of Switzerland. Vox Sang 2011; 101 (Suppl 1): 50-51.
95. Lizardo B, Braukmann K, Ludtke I, Hellmann I, Geusendam G,. Implementation of 5 buffy coat pooled platelet components treated with the INTERCEPT blood system™: experience in German Red Cross blood donation service nord. Vox Sang 2010; 99 (Suppl 1): 258-259.
96. Malvaux N, Courrier P, Collart M,. Validation of pooled buffy coat platelet components suspended in a mixture of plasma and SSP+ treated with INTERCEPT™ pathogen inactivation at Center for Transfusion Services (CTS) in Luxembourg. Vox Sang 2010; 99 (Suppl 1): 253.